Literature DB >> 8054839

Pattern of inhibition of parasympathetic activity in response to incremental bolus doses of atropine in carotid sinus hypersensitivity.

R A Kenny1, S J McIntosh, H Wynne.   

Abstract

Patients with established reproducible cardioinhibitory carotid sinus hypersensitivity were studied to define the dose of atropine required to abolish the heart rate slowing in response to carotid sinus massage, the heart rate response to the Valsalva manoeuvre and salivary gland flow. Bolus doses of intravenous atropine were given to a cumulative dose of 700 mcg. Cardioinhibition was abolished in all patients with a total dose of 700 mcg. The heart rate ratio during the Valsalva manoeuvre did not vary significantly. The decline in salivary gland flow was evident earliest, at a dose of 75 mcg. In clinical studies, 700 mcg of atropine will abolish the diagnostic cardioinhibitory response to carotid sinus message in patients with the syndrome. This may not prevent syncope, as could occur in the key frequent vasodepressor form of carotid sinus hypersensitivity syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054839     DOI: 10.1007/bf01828840

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  21 in total

1.  Heart rate and blood pressure responses to carotid sinus massage in healthy elderly subjects.

Authors:  S J McIntosh; J Lawson; R A Kenny
Journal:  Age Ageing       Date:  1994-01       Impact factor: 10.668

2.  The binding of antagonists to brain muscarinic receptors.

Authors:  E C Hulme; N J Birdsall; A S Burgen; P Mehta
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

3.  Alterations of postural and Valsalva responses in coronary heart disease.

Authors:  F E Tristani; D G Kamper; D J McDermott; B J Peters; J J Smith
Journal:  Am J Physiol       Date:  1977-12

4.  Autonomic reflexes in patients with cardioinhibitory carotid sinus syncope.

Authors:  R A Kenny; J A Allen; W F Wallace
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

5.  Carotid sinus hypersensitivity and syncope.

Authors:  P F Walter; I S Crawley; E R Dorney
Journal:  Am J Cardiol       Date:  1978-09       Impact factor: 2.778

6.  Carotid sinus massage, eyeball compression, and head-up tilt test in patients with syncope of uncertain origin and in healthy control subjects.

Authors:  M Brignole; C Menozzi; L Gianfranchi; D Oddone; G Lolli; A Bertulla
Journal:  Am Heart J       Date:  1991-12       Impact factor: 4.749

7.  Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly.

Authors:  S J McIntosh; J Lawson; R A Kenny
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

8.  Carotid sinus syncope treated by pacing. Analysis of persistent symptoms and role of atrioventricular sequential pacing.

Authors:  C A Morley; E J Perrins; P Grant; S L Chan; D J McBrien; R Sutton
Journal:  Br Heart J       Date:  1982-05

9.  Value of non-invasive continuous blood pressure monitoring in the detection of carotid sinus hypersensitivity.

Authors:  C J Mathias; E Armstrong; N Browse; K R Chaudhuri; P Enevoldson; R W Russell
Journal:  Clin Auton Res       Date:  1991-06       Impact factor: 4.435

10.  Sympathoinhibition and hypotension in carotid sinus hypersensitivity.

Authors:  M L Smith; K A Ellenbogen; D L Eckberg
Journal:  Clin Auton Res       Date:  1992-12       Impact factor: 4.435

View more
  2 in total

1.  Temporary cardiac arrest in patient under robotically assisted total thyroidectomy causing carotid sinus hypersensitivity -A case report-.

Authors:  Hyun Sik Chung; Chong Min Park; Eun Sung Kim; Bo Gyoung Ghil; Chul Soo Park
Journal:  Korean J Anesthesiol       Date:  2010-12-31

2.  Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions.

Authors:  R A Kenny; F E Shaw; J T O'Brien; P H Scheltens; R Kalaria; C Ballard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.